JLHL Q2 FY27 Results & Earnings Analysis
Sentiment: Good (Confidence: medium)
Earnings Summary
Jupiter Life Line Hospitals reported Q2 FY27 income of INR456.5 cr, EBITDA of INR106.9 cr, and PAT of INR56.4 cr; H1 income INR867.5 cr, EBITDA INR186.2 cr, PAT INR93.9 cr . Key highlight was Dombivli hospital nearing EBITDA breakeven (INR0.2 cr loss vs INR9.5 cr in Q1), though partly aided by seasonal infectious disease benefit . The company acquired Pune South land for INR150 cr and has three projects in progress (Pune South, Mira Bhayandar, BKC) . Management refrained from providing financial guidance . Regulatory risks from Supreme Court scrutiny on healthcare pricing and oncology drug margin cap remain unquantified . Debt ceiling of 3x EBITDA provides financial discipline .
Management Tone
- Prepared Remarks: Good — Management highlighted the Pune South land acquisition, on-schedule projects, and continued ramp-up at existing hospitals. Financial performance was presented positively but without detailed drivers .
- Q&A Session: Neutral — Analysts asked detailed questions on Dombivli's breakeven sustainability, margin impacts from regulatory actions on oncology drugs, and capital allocation. Management responses were cautious, often citing inability to quantify impacts or provide forward guidance .
Revenue Growth Drivers
- Dombivli hospital ramp-up with mid-30s occupancy
- Indore facility top-line growth ~18% YoY
- Seasonal higher infectious disease burden boosting Q2 occupancy
Growth vs Margin Focus
Management is investing in growth through new hospitals (Pune South, Mira Bhayandar, BKC) and bed additions while maintaining focus on profitability via 3x EBITDA debt ceiling and 2-year EBITDA breakeven targets for new hospitals . Dombivli achieving near-breakeven ahead of schedule demonstrates ba
About Jupiter Life Line Hospitals Limited
Jupiter Life Line Hospitals Limited (JLHL) is listed on NSE. View the latest earnings analysis, AI-powered insights, and sentiment data on StockMirror.